1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-43.54%
Cash & equivalents declining -43.54% while Biotechnology shows -10.93% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -9.43%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Current assets growth ≥ 1.5x the Biotechnology median of -6.82%. Joel Greenblatt sees a potential liquidity edge if well allocated.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
≥ 1.5x the Biotechnology median of -4.39%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-14.50%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.61%
Below half Biotechnology median of -0.79%. Joel Greenblatt sees more conservative short-term leverage than peers.
6.57%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
7.49%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-3.05%
Near Biotechnology median of -2.92%. Charlie Munger sees typical yoy changes in retained earnings.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
1.25-1.5x Biotechnology median of -6.28%. Mohnish Pabrai notes above-average net worth expansion.
-43.54%
≥ 1.5x Biotechnology median of -4.00%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
8.17%
Near Biotechnology median 10.85%. Charlie Munger sees typical yoy changes in net debt among the sector.
